UNIverse - Public Research Portal
FEMALEavatar

Prof. Dr. med. Anne Leuppi-Taegtmeyer

Department of Clinical Research
Profiles & Affiliations

Medication safety

Summary: My research interest is in the field of medication safety. As lead patient safety officer for the university hospital of Basel and a titular professor for Clinical Pharmacology and Toxicology, I see my role in investigating medication safety issues and using this information to prevent adverse drug events for our patients. Methods include case-control, cohort, feasibility, pharmacokinetic and pharmacovigilance studies.


Research focus und area of research

Our research focus is medication safety - an area that I started working in more than 15 years ago. For my PhD thesis at Imperial College, University of London, UK, I investigated genetic and phenotypic questions about immunosuppression after heart transplantation. In collaboration with the Swiss Toxicological Information Center, I later went on to investigate the safety of overdoses with various immunosuppressants.

As Head of the medication safety program at the University Hospital of Basel, and Head of Patient Safety, I am also interested in the field of medication management. Over the years, we have examined the roles of clinical pharmacologists and electronic support systems in the medication prescription process in hospitals and have adapted an electronic-assisted trigger tool for surveillance of adverse drug events. Other collaborative studies have included the study of the pharmacokinetics of drugs during renal replacement procedures, risk factors for the development of agranulocytosis during treatment with metamizole, and the use and safety of statins in hematopoietic stem cell transplant patients. A further research area of our group is cohort studies in pharmacovigilance. We have examined the safety of azole antifungal agents, COVID-vaccines, checkpoint inhibitors and oral anticoagulants in large patient collectives.

Ongoing projects reflect the diverse nature of medication safety research. Our current areas of research are the safety of opioids used in the hospital setting as indicated by naloxone-administration, the feasibility of conducting a best possible medication history in the emergency department, adherence to Smarter Medicine guidelines for acute lower back pain, length of treatment with oral corticosteroids in chronic obstructive pulmonary disease (a pharmacoepidmiological study), complications of vascular access devices and the user-acceptability of an electronic prescribing tool.  

Selected Publications

Mehra, Tarun, Dongre, Kanchan, Boesing, Maria, Frei, Patricia, Suenderhauf, Claudia, Zippelius, Alfred, Leuppi, Joerg D., Wicki, Andreas, & Leuppi-Taegtmeyer, Anne B. (2023). Pre-treatment comorbidities, C-reactive protein and eosinophil count, and immune-related adverse events as predictors of survival with checkpoint inhibition for multiple tumour entities. Cancer Medicine, 12(11), 12253–12262. https://doi.org/10.1002/cam4.5919

URLs
URLs

Isaak J, Boesing M, Potasso L, Lenherr C, Luethi-Corridori G, Leuppi JD, & Leuppi-Taegtmeyer AB. (2023). Diagnostic Workup and Outcome in Patients with Profound Hyponatremia. Journal of Clinical Medicine, 12(10). https://doi.org/10.3390/jcm12103567

URLs
URLs

El Saghir A, Dimitriou G, Scholer M, Istampoulouoglou I, Heinrich P, Baumgartl K, Schwendimann R, Bassetti S, & Leuppi-Taegtmeyer A. (2021). Development and Implementation of an e-Trigger Tool for Adverse Drug Events in a Swiss University Hospital. Drug, Healthcare and Patient Safety, 13, 251–263. https://doi.org/10.2147/DHPS.S334987

URLs
URLs

Leuppi-Taegtmeyer, Anne B., Reinau, Daphne, Yilmaz, Stella, Rüegg, Stephan, Krähenbühl, Stephan, Jick, Susan S., Leuppi, Jörg D., & Meier, Christoph R. (2021). Antiseizure drugs and risk of developing smoking-related chronic obstructive pulmonary disease or lung cancer: A population-based case-control study. British Journal of Clinical Pharmacology, 87(3), 1253–1263. https://doi.org/10.1111/bcp.14501

URLs
URLs

Premstaller M, Perren M, Koçack K, Arranto C, Favre G, Lohri A, Gerull S, Passweg JR, Halter JP, & Leuppi-Taegtmeyer AB. (2018). Dyslipidemia and lipid-lowering treatment in a hematopoietic stem cell transplant cohort: 25 years of follow-up data. Journal of clinical lipidology, 12(2), 464–480. https://doi.org/10.1016/j.jacl.2017.11.008

URLs
URLs

Selected Projects & Collaborations

Project cover

Dyslipidaemia and its management in a Swiss haematopoietic stem cell transplant cohort

Research Project  | 2 Project Members

Background: Dyslipidemia is common after hematopoietic stem cell transplantation (HSCT). Few data regarding the time course of lipid profiles after HSCT, the effect of multiple transplantations, and efficacy and safety of lipid-lowering treatments are available.

Objective: The objective of the study was to determine the prevalence and treatment of dyslipidemia over a 25-year period in a large, single-center cohort.

Methods: One thousand one hundred ninety-six adult patients (≥16 years) who underwent HSCT during 1973 to 2013 and who survived ≥100 days were studied retrospectively.

Results: The prevalence of dyslipidemia before transplantation was 36% and 28% in the autologous and allogeneic groups, respectively (P < .001). Three months after HSCT, the prevalence rose to 62% and 74% (P < .001), and at 25 years, it was 67% and 89%. Lipid profiles were similar after first and subsequent transplants. Baseline dyslipidemia (odds ratio [OR] = 2.72), allogeneic transplant (OR = 2.44), and age ≥ 35 years (OR = 2.33) were independent risk factors for dyslipidemia at 1 year. Lipid-lowering treatment was given to 223 (19%) patients, primarily in the form of statins (86%) and was associated with a decrease in total cholesterol from 246 to 192 mg/dL (P < .01) and from 244 to 195 mg/dL (P < .001) in the autologous and allogeneic groups, respectively. There were 10 cases (4%) of muscle symptoms prompting cessation of lipid-lowering therapy, including 1 case of rhabdomyolysis. The OR for dyslipidemia among patients who suffered a cardiovascular event (conditional logistic regression) was 3.5 (95% confidence interval = 1.6-7.7, P = .002).

Conclusion: This study confirms that dyslipidemia is a common and long-lasting phenomenon among both allogeneic and autologous HSCT patients. Statins are effective, generally well-tolerated and should be highly recommended for the management of post-HSCT dyslipidemia.